The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
HOME > LATEST
LATEST
-
BUSINESS Moderna Submits RSV Vaccine in Japan
May 31, 2024
-
BUSINESS Nxera Gets US$4.6 Million Milestone over Centessa’s OX2R Agonist
May 31, 2024
-
REGULATORY Expand Mixed-Billing Scheme to Cover Gene Panel Test: LDP Committee Proposal
May 31, 2024
-
BUSINESS Viatris Launches Cystadrops, Its 1st Brand-Name Product in Japan
May 31, 2024
-
BUSINESS Takeda’s cTTP Drug Adzynma Now Available in Japan
May 31, 2024
-
COLUMN How to Plan for Future Talent Needs
May 31, 2024
-
BUSINESS Kaken to Transfer Bispecific IP to J&J as US Giant Nabs Asset
May 30, 2024
-
REGULATORY Japan Selects JN.1 for COVID-19 Vaccine Formula in 2024-2025 Season
May 30, 2024
-
REGULATORY PMDA Cuts Fees for Pediatric, Orphan Drug Consultations
May 30, 2024
-
BUSINESS AnGes/Vasomune’s ARDS Drug Gets Fast-Track Tag in US
May 30, 2024
-
BUSINESS Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
-
BUSINESS AbbVie Japan Eyes Sales of 200 Billion Yen in 5 Years, Rinvoq and Skyrizi as Drivers
May 29, 2024
-
BUSINESS Boehringer’s Japan Pharma Sales Up 7% in 2023, Buoyed by Ofev, Jardiance
May 29, 2024
-
BUSINESS Nippon Shinyaku Chief Defends Benefits of DMD Therapy after PIII Miss
May 29, 2024
-
BUSINESS Novel Antibiotic Fetroja Now Available in Taiwan: Shionogi
May 29, 2024
-
REGULATORY LDP Lawmakers’ League on Generics Prods Minister to Rethink Off-Year Revisions
May 29, 2024
-
BUSINESS Cheplapharm to Take Over 2 More Brands from Clinigen in Japan
May 29, 2024
-
BUSINESS Fuji Pharma Charts Its Future as Japan’s Leading Biosimilar Player, Stelara Follow-On as Pace Setter
May 28, 2024
-
BUSINESS Nippon Shinyaku’s DMD Drug Misses Mark in Confirmatory Study
May 28, 2024
-
BUSINESS Daiichi Sankyo’s TROP2 ADC Shows OS Benefit in Subgroup of NSCLC
May 28, 2024
ページ
The pharmaceutical industry is ever-changing. Recruiters must evolve accordingly and prepare well in advance for future talent needs.This means predicting the changes and trends that will impact the market, industry, and your organization, and how this will affect talent requirements.…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…